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Abstract: Nearly 3 decades ago, a dendritic structure was stepwise synthesized for the first time as a new type of mole-
cules with promising applications. During years a huge effort has been devoted to implement the synthetic skills concern-
ing the synthesis of these molecules and especially, new methods for purification and characterization of these compounds 
that are in the nanoscale range. The chemical manipulation of the surface and inner core of dendrimers were strategically 
used to allow a tailor-made control of physical-chemical properties and to discover new applications in material science 
and biomedicine. Although several examples have been reported in the literature describing applications of functionalized 
dendrimers and acclaiming a key role of these molecules, very scarce examples are actually close to the market. 
This review summarizes the state of the art of dendrimers and dendritic polymers as anti-infective agents, with a special 
focus on the strategies to block receptors used by pathogens for attachment, cell entry and dissemination. These nanome-
tre size molecules are very attractive compounds as new drugs easily to be manipulated to improve their activity and 
scope. This is already a very active area of research, where we are involved, with interesting potential as demonstrated by 
the Phase I clinical trial of a functionalized dendrimer with real possibilities to reach the market soon. The success of this 
compound should provoke an enormous stimulus to scientists working in this area as well as in the industrial companies 
for investment in this topic.  
INTRODUCTION 
 At the end of the 70’s the first cascade molecule was syn-
thesized and characterized as a new type of chemical struc-
ture [1]. These new hyperbranched structures which resem-
ble the branches of a tree were named dendrimers from the 
greek word dendron (meaning tree). The properties of den-
drimers are mainly governed by the functional groups pre-
sented at the surface of these structures. The possibility to 
manipulate and change the nature of these functional groups 
open the opportunity to create tailor-made structures with 
broad spectra of application in different areas such as mate-
rial science, catalysis, biomedicine, etc. These tree architec-
tures were developed during two decades and an intense 
work was devoted to describe new synthetic methodologies 
to achieve so complex structures. Many isolation and purifi-
cation problems were faced together with a critical point that 
still nowadays is considered a big challenge, the characteri-
zation of this type of molecules. Several good reviews re-
cently published summarize the advances in this field con-
cerning dendrimer synthesis and the state of the art [2-5]. 
Also, there are several reviews concerning the biological 
applications of dendrimers [6-12]. The aim of this review  
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will be focus mainly on the applications of these types of 
structures as antimicrobial agents with special interest on 
those examples applied to in vitro and in vivo studies. This is 
one of the applications in the biomedical area that has at-
tracted the interest of scientists working on these dendritic 
architectures, mainly dendrimers, dendronized and dendritic 
polymers, and related molecules. This review is divided into 
different sections based on the infective agents but not in 
dendrimer structures. The nature of these dendrimers is di-
verse although in most cases these structures are functional-
ized with carbohydrates (glycodendrimers). We will describe 
the basic characteristic of these dendrimers and overview the 
infection processes where dendrimers have been used as an-
timicrobial agents.  
IMMUNOLOGICAL RECOGNITION OF PATHO-
GENS 
 Innate immunity has experienced an enormous progress 
in the last few years with the discovery and characterization 
of several families of receptors whose principal function is 
the recognition of invading microorganisms as predicted by 
Janeway [13]. These molecules recognized highly conserved 
motives on the surface of pathogens (pathogen-associated 
molecular patterns, PAMPs), hence the name of “pattern-
recognition receptors” (PRRs). The role of these diverse 
molecules in immune response is also complex. Toll-like 
receptors (TLRs) participate in the detection of a wide spec-
trum of PAMPs, being bacterial LPS recognition by TLR-4 
the most representative example [14]. TLRs trigger a cascade 
of signalling that elicit a number of responses and connect 
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innate and adaptative immunity [14]. The intracellular family 
of NOD-like receptors (NLRs) also participates in pathogen 
recognition and regulation of immune response. An imbal-
ance in the function of some members of NLRs has been 
recently related to important inflammatory illnesses such as 
Crohn disease [15]. Targeting TLRs and NLRs to regulate 
immune response is nowadays an area of intense research. C-
type lectin receptors (CLRs) is an additional family of PRRs 
mainly expressed or secreted by myeloid cells whose mis-
sion in immune response includes both recognition of patho-
gens and intercellular signalling between immune competent 
cells [16]. CLRs exhibit different structures and properties 
but all have a carbohydrate-recognition domain (CRD) with 
a distinct specificity (Table 1).  
 It is increasingly clear that some microorganisms subvert 
the functionality of these receptors to gain access to cells and 
tissues. It is this role facilitating attachment and entry of 
pathogens that makes CLRs an interesting target to design 
anti-infective strategies. DC-SIGN is a CLR in which these 
characteristics exemplify most clearly.  
 DC-SIGN (Dendritic-Cell-Specific ICAM-3 Grabbing 
Non integrin) was characterized by Geijtenbeek et al. while 
searching for a ligand in Dendritic cells (DCs) for ICAM-3 
in T-lymphocytes [20,32]. The gene had been identified 
years before as a part of a screening for cellular products 
with affinity for gp120, the principal component of HIV en-
velope, using a placental expression library [33]. The coinci-
dence in DC-SIGN of expression on DCs, HIV binding and 
participation in cellular immune cross talk elicited great in-
terest. It was shown that DC-SIGN is not a true viral receptor 
but what was called a trans-receptor: HIV can bind to DC-
SIGN and take advantage of this interaction since the viral 
particle, that normally has a half life of a few hours, is inter-
nalized and can be presented to susceptible CD4+ T-
lymphocytes days after without minimal loss of infectivity. 
Soon it was also shown that DC-SIGN was a receptor for 
other important pathogens such as Ebola virus [23], Myco-
bacterium tuberculosis [22] or Cytomegalovirus [21]. It has 
been demonstrated that DC-SIGN recognizes high-mannose 
N-linked carbohydrates present in substantial amounts as 
part of the envelope glycoproteins of these microorganisms. 
Within the glycosylation moiety, the CRD of DC-SIGN 
binds preferentially to the outer trimannose branch Man1-3 
[Man1-6]Man [34]. The characterization of DC-SIGN in 
DCs, and its closely related homologue DC-SIGNR or L-
SIGN in certain subsets of endothelial cells from liver sinu-
soids and lymph nodes [35], along with the increasing num-
ber of pathogens recognized by the receptor has greatly 
stimulated research on the molecule and potential applica-
tions. However the precise role that DC-SIGN plays in these 
infections is not completely understood in part due to the 
lack of a suitable animal model since mice have multiple loci 
of the murine counterpart with somewhat different 
specificities [36]. The best proof of the biological relevance 
of DC-SIGN in immune response is demonstrated by the 
impact on infection of different genetic polymorphisms in 
DC-SIGN found in population studies. It has been shown 
that a polymorphism in the promoter region is strongly corre-
lated with a severe form of Dengue fever [37] and different 
polymorphisms of the molecule appear to be also related to 
different clinical course in HIV infection [38-40]. However, 
the precise mechanisms that explain these different responses 
related to DC-SIGN forms remain to be elucidated in future 
studies along with the potential to use DC-SIGN as a target 
to prevent or treat infection. 
 Another interesting application based in the unique prop-
erties of DC-SIGN is the use of the molecule to deliver anti-
gens for immunization to DCs. The natural properties of DCs 
in antigen uptake and presentation to T cells through MHC 
molecules could increase the response obtained with vaccine 
candidates in cancer and infectious diseases [41]. It has been 
demonstrated, both in vitro and in vivo, that antigens bound 
to DC-SIGN antibodies undergo uptake by DCs and are effi-
ciently presented to T-lymphocytes thus inducing prolifera-
tive responses [42-44]. Dendrimers, as it will be shown be-
low, are promising candidates to target this molecules either 
to block pathogen binding or to deliver antigens to particular 
cell subsets. 
BACTERIAL INFECTION 
 Bacterial are common infective agents producing a wide 
variety of diseases. Bacteria are still an important cause of 
Table 1. C-type Lectins and Specific Ligands: ManLAM, (Mannosylated Lipoarabinomannan). Le, (Lewis). GlcNAc, (N-
acetylglucosamine). GalNAc, (N-acetylgalactosamine). HIV, (Human Immunodeficiency Virus). HCV, (Hepatitis C Vi-
rus). CMV, (Cytomegalovirus). SARS, (Severe Acute Respiratory Syndrome) [17] 
CLR Carbohydrate recognition Pathogen 
MR (CD206) Mannose HIV, Mycobacteria, Fungi [18,19] 
DC-SIGN (CD209) 
Mannan, High mannose glycosylation, ManLAM, Fucose, 
LeX,A,Y,B
HIV, Ebola virus, HCV, CMV, Dengue virus, Mycobacteria, 
Leishmania [20-25] 
Dectin-1 ?-1,3-glucans Fungi [26] 
Dectin-2 High mannose glycosylation C. albicans [27] 
Langerin (CD207) Mannose, GlcNAc, Fucose HIV [28] 
hMGL GalNAc Schistosoma, Ebola virus [29] 
LSECtin ? Ebola virus, SARS virus [30,31] 
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mortality in developed countries and the origin of massive 
epidemics that spread very easily among the population of 
developing countries due to the lack of adequate sanitary 
conditions. Additionally, some bacteria are responsible to 
produce highly potent toxins that can be considered as bio-
logical warfare. The search for therapeutic and prophylactic 
agents against these toxins is a topic of extreme importance 
[45].  
 The broad use and sometimes abuse of antibiotics has 
contributed to the appearance of bacterial resistance that has 
forced the biomedical researchers to look for new strategies 
to combat bacterial infections. One of the most attractive 
alternatives is the inhibition of bacterial attachment to target 
cells during the first stages of the infection using antiadhe-
sive molecules. Bacteria adhesion is mediated by specific 
carbohydrate-protein interactions between lectin-like pro-
teins at the surface of bacteria and glycoconjugates (glyco-
proteins and glycolipids) at the surface of target cells or 
viceversa. Blocking this interaction should inhibit the at-
tachment of bacteria to the target cell surface and stop the 
infection. Although carbohydrate-protein interactions are 
weak (tipically with affinities at the milimolar range) the 
efficiency of this recognition process is achieved in nature 
due to the presence of multivalent interactions. Several ap-
proaches have been conceived to inhibit this recognition 
process, basically developing carbohydrate multivalent com-
pounds such as glycodendrimers and glycodendritic poly-
mers. In this section, we will review the design and synthesis 
of dendrimers (most of them, glycodendrimers) used as po-
tential antibacterial drugs. The classification of so many dif-
ferent structures described in the bibliography will be done 
in this review based on the type of bacteria target. 
Bacteria Producing AB5 Toxins 
 This is a very important group of Gram-negative bacteria 
which produce toxins causing thousands of deaths every 
year. These toxins present six subunits, one A subunit that is 
responsible of the infection and a homopentameric B 
subunits (B5) that are required for the attachment of the toxin 
to the cell surface. Inhibition of the attachment of the 
subunits B5 should be enough to stop the infection process. 
This B unit presents a carbohydrate recognition site that in-
teracts with carbohydrates present at the cell surface in a 
multivalent way (five simultaneous interactions between B5
and cell surface carbohydrates). 
Cholera Toxin 
 Cholera toxin is an AB5 protein secreted by Vibrio chol-
erae causing the disease cholera. This is an infectious intes-
tinal disease characterized by severe diarrhea, and vomiting 
that if untreated may be life-threatening due to enormous 
loss of water and electrolytes. The B subunit is able to rec-
ognize and interact with ganglioside GM1 at the cell mem-
brane forming a pore for subunit A that blocks GTPase activ-
ity of G protein and results in an increase of the synthesis of 
cAMP. In the intestine this leads to watery, electrolyte rich 
diarrhea as Cl- leaves the cells followed by Na+ and water.  
 The Schengrund group has developed oligosaccharide 
functionalized dendrimers to inhibit the binding of the B5
subunit to cell surface GM1 [46,47]. The dendritic cores 
used were tetra (1st generation) (1) and octa(propylene 
imine) (2nd generation) (2) dendrimers and the 1st generation 
of StartburstTM (PAMAM) (3) (Fig. 1).  
 These scaffolds were functionalized with the carbo- 
hydrate moiety of ganglioside GM1 (Gal?1-3GalNAc?1-4
[NeuNAc?2-3]Gal?1-4Glc) (oligo-GM1) by reaction with a 
phenylisothiocyanate derivative of this oligo-GM1. The av-
erage number of sugars at the surfaces of dendrimers 1, 2
and 3 was 4, 7, and 6 respectively. The inhibition studies 
were performed using a 125I-labeled cholera toxin B subunit 
(125I-CT-B) and GM1-coated wells [46]. The IC50 found 
were 3 nM for octa(propylene imine), 7-8 nM for 
tetra(propylene imine) and StarburstTM, 45 nM for GM1 and 
10?M for oligo-GM1. These results represented a 250 fold 
increase of activity for multivalent systems in comparison 
with the monovalent natural oligosaccharide. Cellular ex-
periments were performed using NCTC-2071 murine fibro-
blast expressing GM1 in a controlled way and (125I-CT-B) to 
explore the physiological interest of these dendrimers [47]. 
Octa( propylene imine) produced a clear inhibition effect of 
the adherence of CT-B to cell expressing GM1 at the surface. 
In summary, the authors concluded that these types of oligo-
saccharide functionalized dendrimers could serve as effec-
tive ligands for pathogens that adhere to oligosaccharides 
present at the target cell surface. 
 Pieters et al., have prepared dendrimers with a significant 
rigid backbone using 3,5-bis(2-aminoethoxy)benzoic acid as 
repeating unit [48]. Dendrimers of first G1 (4), second G2 
(5), and third G3 (6) generations presenting 2, 4, and 8 lac-
tose as sugars (R1 in Fig. 2) were prepared and characterized 
(Fig. 2).  
 The affinity of these compounds for cholera toxin B 
subunit was measured using fluorescence spectroscopy. CTB 
present a tryptophan (Trp 88) at the carbohydrate binding 
site which fluorescence is quenched by bound ligand. In 
these studies, apparent KD of 235 ?M, 99 ?M, and 33?M
were found for divalent (4), tetravalent (5), and octavalent 
(6) compounds respectively. The monovalent lactose gave a 
KD of 18 mM, 545 fold less potent than the octavalent den-
drimer. In this study was also pointed out the importance of 
the size and shape of the spacer used to attach the carbohy-
drate moiety to the dendritic core. 
 Bernardi and Pieters groups have prepared a dendrimer 
using the same dendritic core described above functionalized 
with a GM1 mimic (R2 in figure 2) [49]. This system was 
tested for CTB binding using two techniques, SPR analysis 
and ELISA assays. The SPR gold chip was functionalized 
with a glycoprotein which carbohydrate moieties are good 
ligand for CTB. In these studies were found the following 
inhibition activities: lactose an IC50 of 9.4 mM, monovalent 
GM1 mimic an IC50 of 97 ?M, the divalent compound (4,
R2) an IC50 of 13?M (17-fold enhanced respect to the mono-
valent), the tetravalent compound (5, R2) an IC50 of 0.5?M
(111-fold increased) and the octavalent compound (6, R2) an 
IC50 of 0.5 ?M. The higher relative potency (per sugar) of 
the tetravalent system in comparison with the octavalent one 
was explained due to this compound reached the limit of the 
assay. A different assay based on ELISA was performed 
with the aim to evaluate the activity of this octavalent com-
pound. The ELISA wells were coated with the ganglioside 
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Fig. (1). Chemical structures of poly(propylene imine) (PPI) G1 (1) and G2 (2); and dendrimer PAMAM G1 (3) functionalized with carbohy-
drate moiety of ganglioside GM1. 
Fig. (2). Dendritic structures of G1 (4), G2 (5), and G3 (6) generation based on 3,5-bis(2-aminoethoxy)benzoic acid functionalized with lac-
tose (R1) and Lewis X mimic (R2). 
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GM1 and a CTB-horseradish peroxidase conjugate was used 
as binding protein. Only this octavalent system presented 
some inhibitory activity in these assays (20% of inhibition at 
400 ?M concentration of compound). These results demon-
strated the high-affinity of this GM1 mimic ligand on a mul-
tivalent scaffold for this AB5 toxin. Also, it was demon-
strated that the design of multivalent scaffolds for this toxins 
are not as important as the right design of the ligand. 
Shiga and Vero Toxins 
 Shiga toxins (Stx1 and Sxt2), produced by Shigella dys-
enteriae and Shiga-like toxins (SLT-I and SLT-II) also 
called Vero toxins produced by Escherichia coli O157:H7, 
are AB5 toxins causing watery diarrhea or hemorrhagic coli-
tis respectively that are particularly severe in children and 
elder people being responsible of millions of episodes 
around the world.  
 One of the more remarkable example in the rational de-
sign of multivalent systems for the inhibition of SLTs was 
described by Bundle et al., in a leading article few years ago 
[50]. Although it can not be considered as a dendrimer 
strictly speaking, the carbohydrate multivalent systems 
named STARFISH designed by Bundle et al., will be dis-
cussed here. The oligosaccharide receptor for shiga-like 
toxin on mammalian cells is the Gb3 glycolipid (Gal?1-
4Gal?1-4Glc?1-OCer). The corresponding trisaccharide was 
used as ligand to create a multivalent system presenting 10 
carbohydrate units (Fig. 3).  
Fig. (3). Chemical structure of STARFISH and DAISY multivalent systems functionalized with globotriaose. 
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 In an ELISA assay, using 96-well plates coated with the 
trisaccharide and SLT-I and SLT-II in the presence or ab-
sence of inhibitors, were found for the STARFISH com-
pound IC50 = 0.4 nM (STL-I) and IC50 = 6 nM (STL-II), a 
million-fold increase in comparison with the corresponding 
monovalent ligand. A crystal structure was obtained reveal-
ing the mode of binding of this STARFISH molecule. A 2:1 
(Shiga toxin-STARFISH) sandwich complex was observed 
as a thermodynamically more stable complex. The findings 
of this work confirmed the potential use of multivalent car-
bohydrate systems as bacterial anti-adhesive therapeutics. 
Some years later, the therapeutically activity of STARFISH 
molecule was tested in mice using both Stx1 and Stx2 [51]. 
This molecule was able to protect mice inoculated subcuta-
neously with a lethal dose of Stx1 with a 90% survival rate 
(inhibitor/toxin molar ratio of 103:1) and with 100% survival 
rate (inhibitor/toxin molar ratio of 104:1). However, this 
compound was not effective in protecting mice inoculated 
with Stx2. A modified version of STARFISH named DAISY 
whose major difference is the attachment of the sugar moiety 
to the multivalent scaffold through the anomeric position of 
the reducing end instead of position 2 of central galactose, 
was also tested (Fig. 3). DAISY was able to protect mice at 
100% from both Stx1 and Stx2 in the toxin coadministration 
at molar ratios 2 x 103:1 and 105:1 respectively. Subcutane-
ous injection of DAISY would create subcutaneous depot 
and would deliver the drug to reach target organs of Stx in a 
period of time sufficient to be therapeutically efficient but 
this was not confirmed. However, the authors indicated that a 
continuous intravenous infection in humans could be the 
most adequate way for a treatment (the clearance of DAISY 
from circulation via galactose-specific receptors in liver 
could be a problem to reach effective concentration in blood 
with a single dose). These very promising results will stimu-
late the search for new drugs based on carbohydrate multiva-
lent systems as anti-adhesive compounds. 
 Using carbosilane dendrimers functionalized with the 
same Gb3 trisaccharide, Nishikawa et al., have studied the 
inhibition of infection by shiga toxin-producing E. coli
0157:H7 [52]. These dendritic structures named SUPER 
TWIG are constituted by a core of silicon-carbon bonds that 
are biologically inert. SUPER TWIGs (0)3, (1)6, and (1)12 
containing 3, 6, and 12 trisaccharides respectively were pre-
pared (Fig. 4).  
 The IC50 (?g/mL) found in the inhibition of binding ex-
periments in vitro of Stx1 and Stx2 to Vero cells are summa-
rized in the Table 2. SUPER TWIGs (1)6, and (1)12 were 
able to inhibit the cytotoxicity of Stx1 and Stx2 towards 
Vero cells but not SUPER TWIGs (0)3. 
 In vivo studies in mice were performed inoculating intra-
venously a lethal dose of Stx2. Surprisingly, SUPER TWIG 
(1)6 was able to suppress the effects of Stx in a concentration 
of 5 ?g/g of body weigh but mice treated with SUPER 
TWIG (1)12 did not survive more than 7 days. Apparently, 
other factor than the pure inhibition of adhesion (as observed 
in vitro) had to play an important role in the infection proc-
ess in vivo. SUPER TWIG (1)6 was also able to protect mice 
from an oral infection with E. coli O157:H7. Analysis of the 
in vivo and in vitro results provided significant evidences to 
propose a dual mechanism of action in vivo of SUPER 
TWIG (1)6 based on a) inhibition of the Stx adhesion to the 
target cell expressing globotrioside glycolipid, and b) induc-
tion of Stx uptake by macrophage. These preliminary results 
were performed with a first series of carbosilane dendrimers. 
Modifications of dendrimer structures concerning the num-
ber of carbohydrates at the surface of the dendrimers and the 
core structure were carried out by this group with the aim to 
optimize the inhibition activities [53,54]. 
Fig. (4). Chemical structure of dendrimers SUPER TWIG (0)3, 
(1)6, and 1(12) functionalized with globotriaose. 
Table 2. Inhibition (IC50 (?g/mL) of Binding Experiments 
Using Stx1, Stx2 and Carbosilane Dendrimer 
SUPER TWIGS 
Dendrimer Stx1 Stx2 
SUPER TWIG (0)3 >40 >100 
SUPER TWIG (1)6 0.22 2.3 
SUPER TWIG (1)12 0.16 1.3 
 Several new structures derived from SUPER TWIGs de-
scribed before were designed and synthesized with the aim to 
improve the optimal function in circulation against shiga 
toxin (Fig. 5) [53].  
 Structures from 0 to 2 generation presenting up to 36 
carbohydrates were prepared and tested. A kinetic analysis of 
binding of Stx1 and Stx2 to these structures was carried out 
using biosensors. The KD values found for SUPER TWIGs 
with 4, 6, 9, 12, 18, and 36 trisaccharides with respect to 
both Stxs were very similar. The inhibition activity of these 
dendrimers for the adhesion of 125I-labeled Stx to Vero cells 
was measured. The IC50 found for SUPER TWIGs (1)4, (1)9, 
(2)18, and (2)36 with 4, 9, 18, and 36 carbohydrates respec-
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Fig. (5). Chemical structure of dendrimers SUPER TWIG (0)4, (1)4, (1)9, (2)18, and 2(36) functionalized with globotriaose. 
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Fig. (6). Chemical structure of dendrimers Fan (1)3, Dumbbell 2(4), (2)6 functionalized with globotriaose and galobiose.
tively were 0.43, 0.34, 0.21, and 0.21 ?mol/L for Stx1 and 
1.4, 11.0, 2.1, and 9.5 ?mol/L for Stx2 respectively. In com-
parison with the previous SUPER TWIG (1)6, only the struc-
ture of second generation containing 18 carbohydrates 
(SUPER TWIG (2)18) showed a better activity against Stx1 
and Stx2. In vivo studies were performed with these new 
compounds as well. Using a lethal dose of Stx2 intrave-
nously administered to mice, only SUPER TWIG (2)18 sup-
pressed 100% the effect and mice survived for more than 2 
months. Taking into account these biological results and the 
chemical structures of the dendritic compounds used, some 
important considerations were assessed: a) at least 4 trisac-
charides were required for high affinity and at least 6 trisac-
charides are required for an effective activity in vivo; b) dis-
tance between terminal silicon atoms in the core structure 
should be at least 11 Å; c) terminal trisaccharides with spac-
ers must be branched from the same terminal silicon atom to 
present a high density. 
 Another work of the same group was published very re-
cently presenting a new study on carbosilane dendrimers 
[54]. Based on the distance between adhesion points in Stx 
(around 46 Å), the distance between carbohydrates in the 
SUPER TWIG (1)6 structure (renamed now as Dumbbell 
(2)6) was not long enough. A new series of carbosilane den-
drimers were prepared presenting 3 (Fan (1)3), 4 (Dumbbell 
(2)4) and 6 (Dumbbell (2)6) disaccharide galabioses (Gal?1-
4Gal) respectively (Fig. 6).  
 The activity of these new compounds was assessed using 
biosensor to measure the dissociation constants to Stx1 and 
Stx2 as is shown in Table 3 [54].  
 However, the best result was one order of magnitude 
worst than the previous data found for Dumbbell (1)6. The 
IC50 found for inhibition of binding assays of 125I-labeled 
Stxs and Vero cells are presented in Table 4.
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Table 3. KD(?M) Measurements Using Biosensors for Car-
bosilane Dendrimers Against Stx1 and Stx2 
Dendrimers Stx1, KD (?M) Stx2, KD (?M) 
Fan (1)3 Galabiose 61.1 53.9 
Dumbbell (1)4 Galabiose 10.5 10.1 
Dumbbell (2)6 Galabiose 1.3 1.6 
Fan (0)3 Globotriaose 64.8 124 
Dumbbell (1)6 globotriaose 0.11 0.21 
Table 4. IC50 (?M) for Inhibition of Binding Assays with 
Carbosilane Dendrimers and Stx1 and Stx2 
Dendrimers Stx1, IC50 (?M) Stx2, IC50 (?M)
Fan (1)3 Galabiose 18.9 17.8 
Dumbbell (1)4 Galabiose 23.6 23.6 
Dumbbell (2)6 Galabiose 14.2 13.6 
Fan (0)3 Globotriaose 21.4 >50 
Dumbbell (1)6 Globotriaose 0.08 0.50 
 Again, the results for the new synthesized compounds 
were far away of the activity of previously prepared carbosi-
lane dendrimers. The explanation for these results was based 
in the shorter distance found between sugars in the dendrim-
ers which is critical to have good binding affinities for Stxs.  
Heat Labile Enterotoxin 
 The heat labile enterotoxin (LT) of E. coli is a cholera-
like enterotoxin that adheres as cholera toxin does to gangli-
oside GM1 and causes a somewhat less severe diarrhea due 
to the same mechanisms [55]. Based on the structural simi-
larities between cholera toxin and heat labile toxin, the group 
of Schengrund has used the same type of experiments to 
prove the activity of oligosaccharide-derivatized dendrimers 
for cholera toxin and heat labile toxin with similar results 
[46,47].  
Bacterial Endotoxins 
 Gram-negative bacteria such as Haemophilus influenzae, 
Escherichia coli, Salmonella enterica, Kelbsiella pneumo-
niae, Bordetella pertussis, Pseudomonas aeruginosa, Chla-
mydia psittaci, and Legionella pneumophila present at the 
outer leaflet of the bilayer membrane a lipopolysaccharide 
(LPS) component which play a key role in septic shock (sep-
sis syndrome) [56,57]. This LPS is liberated from the mem-
brane surface when bacteria multiply, die or lyse. LPSs have 
been recognized as a factor responsible of toxicity in severe 
Gram-negative bacteria infections causing a systemic re-
sponse that if uncontrolled can lead to septic shock charac-
terized mainly by fever, hypotension, coagulopathy, and or-
gan failure resulting in many cases in death. The toxic moi-
ety of LPS is a glycolipid named Lipid A considered as a 
target for the design of drugs against endotoxins (Fig. 7).  
 This LPS presents an anionic and amphiphilic nature that 
is an important feature for the design of compounds able to 
interact with LPS. 
 David et al., have used polycationic amine-terminated 
poly(amidoamine) (PAMAM) dendrimers as endotoxin 
sponge for the therapy of Gram-negative bacterial sepsis 
(Fig. 7) [58]. Looking for the amphiphilic character of Lipid 
A, the dendrimers were partially (25-80%) alkylated at the 
surface using 1,2-epoxyalkanes. The affinity of these den-
drimers for LPS was evaluated using a high-throughput fluo-
rescence displacement method using BODIPY cadaverine as 
displacement probe. The best ED50 (50% of displacement) 
was 91 nM found for the PAMAM generation 5 derivative 
with a 50% of alkylation (with 2-hydroxyhexyl groups). The 
dendrimer with a 20% of alkylation presented an ED50 of
0.28 ?M. In vitro assays of nitric oxide release in LPS-
stimulated murine macrophage were used to analyze the 
dendrimer activity. Again, the 5th generation of PAMAM 
with 50% of alkylation showed the best IC50 (50 nM). The 
amphiphilic character of these dendrimers partially function-
alized with alkyl groups was critical to achieve good activity 
to neutralize endotoxins. This compound was used for in
vivo studies using mice treated intraperitoneally with a su-
perlethal dose (200 ng/mouse) of LPS. A dose dependent 
protection of septic shock was observer at 24 hours. Moreo-
ver, partial protection was observed up to 36 hours preceding 
the endotoxin administration indicating a highly prolonged 
pharmacokinetics. 
Type 1 Fimbriated Escherichia coli 
 Type 1 fimbriae are adhesion organelles expressed by 
many Gram-negative bacteria and responsible of the adher-
ence of Escherichia coli to the urinary tract causing common 
urinary tract infection [59]. This adhesion process is gov-
erned by the interaction between type 1 fimbriae and man-
nose conjugates found at the bladder epithelial cell surface.  
 Lindhorst et al., have developed carbohydrate multivalent 
systems to inhibit the adhesion of E. coli mediated by 1 fim-
briae. Some of this work was based in simple di, tri and 
tetramannosides that could corresponding to dendrimers of 
generation 0 and will not be reviewed here although is an 
interesting work where some important details about cluster-
ing, linkage position and type of spacer are considered [60-
62]. Glycodendrimers based on multivalent mannopyranosyl 
structures were prepared as potential inhibitors of the adhe-
sion of type 1 fimbriae [63]. Multivalent systems containing 
3 (7), 4 (8), 6 (9), and 8 (10) mannopyranosides attached to 
the scaffold through a thiourea linkage were prepared and 
their activities were tested (Fig. 8).  
 Biological experiments based on inhibition of agglutina-
tion using guinea pig erythrocytes and E. coli were carried 
out. Inhibition titers in these experiments indicated that triva-
lent (7) and hexavalent (9) mannosyl glycocluster were simi-
lar (0.091 mM) and slightly smaller than that found for the 
octavalent (10) compound (0.083 mM). Tetravalent manno-
syl glycocluster (8) presented a higher value (0.26 mM). 
Also, the features of the linker can play an important role to 
establish hydrophobic contact with the receptor as was con-
firmed with the monovalent p-nitrophenyl mannopyranoside 
that showed an inhibition titer of 0.072 mM. Control ex-
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Fig. (7). Lipid A and chemical structures of amine terminated PAMAM derivative dendrimers.
periments using glucose demonstrated the specificity of the 
binding process for mannosyl derivatives. 
 Roy, Lee et al., have synthesized polylysine dendrimers 
with 2 (DP-2), 4 (DP-4), 8 (DP-8), and 16 (DP-16) mannoses 
with the aim of inhibiting the adhesion of E. coli (Fig. 9)
[64].  
 The assay was performed used a neoglycoprotein with 21 
mannoses labelled with 125I (125I-Man21-ALK-HSA) and E. 
coli. The IC50 found were 22, 5, 2.8, and 0.9 nM for den-
drimers presenting 2, 4, 8, and 16 mannoses respectively. 
DP-16 showed an increase of inhibition activity of 12500 
fold in comparison with the monovalent methyl ?-
mannopyranoside. The studies revealed important issues 
concerning the importance of the mannose orientation on 
these types of multivalent systems. The affinity of these 
compounds was strongly dependent on the distance between 
mannose residues; a large distance (> 20 nm) seems to be an 
adequate separation between two mannoses to interact in a 
multivalent way with adhesins presented in 1 fimbriae E. 
coli.
 Pieters et al., have developed small multivalent systems 
[65,66], glycodendrimers [66] and glycopolymers [66] to 
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Fig. (8). Poly(amido amine) dendrimers with 3 (7), 4 (8), 6 (9), and 8 (10) mannopyranoses.
inhibit the adhesion of type 1 fimbriated uropathogenic E. 
coli. Two type of scaffold were prepared based on bis-3-
aminoprop-1-ynyl benzene and PAMAM (Fig. 10).  
 The biological activity was tested in an ELISA-based 
assay using type 1 fimbriated E. coli and T24 cell line de-
rived from human urinary bladder epithelium. These assays 
indicated that systems based on PAMAM were better than 
those based on the aromatic scaffold (for the same number of 
ligand at the surface). PAMAM presenting 8 (3) ((Fig. 3) and 
16 (11)) mannoses showed an IC50 of 37 and 19 ?M respec-
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Fig. (9). Polylysine dendrimers DP-2, DP-4, DP-8 and DP-16 functionalized with mannose. 
Fig. (10). Mannosyl derivative PAMAM 2G (11). 
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tively. The dendrimer with aromatic scaffold (6) (Fig. 2) and 
8 mannoses at the surface showed an IC50 of 72 ?M. Again, 
these studies demonstrated the importance not only of the 
number of ligands but the size and shape of the scaffolds and 
linkers used.  
 One of the general strategies to test the activity of com-
pounds as bactericides is the use of E. coli as a general type 
of Gram-negative bacteria model. Banthia et al., have pre-
pared oligourethane dendronized with PAMAM (Fig. 11)
[67].  
 The activity of these compounds was tested using a 
method to observe inhibition zone of growth with bacteria on 
a solid agar medium. This dendronized system by itself was 
not able to inhibit the bacteria growth; however, when it was 
doped with silver, a clear inhibition was observed. These 
materials could be considered as promising systems for bio-
medical applications. 
 Urbanczyk-Lipkowska et al., have prepared two type of 
dendrimers based into amino acids (Lysine) to inhibit infec-
tion by E. coli [68,69]. Minimal inhibitory concentrations 
(MIC), the concentration at which 100% inhibition of 
growth, were evaluated. The values found for all compounds 
prepared were in the ?M range. 
 Cooper et al. have developed quaternary ammonium 
functionalized poly(propylene imine) dendrimers (12) as 
antimicrobials (Fig. 12) [70].  
 The biocide activity was evaluated using a biolumines-
cence method. Some key structural factors were analyzed 
based on their influence in the activity. The size of the den-
drimer, the length of hydrophobic chain in the quaternary 
group and the counteranion were very important issues. 
Streptococcus suis 
 Streptococcus suis is a Gram-positive bacteria responsi-
ble of meningitis, septicemia, and pneumonia in pigs, swine 
and other domestic animals and also meningitis in humans 
who have been in contact with pigs [71,72]. This bacteria 
present a galactosyl-?-1-4-galactose-binding adhesin impli-
cated in the adhesion process of the bacteria to the host cells 
[73]. Magnusson et al., in 1997 prepared a small tetravalent 
galabiose system to inhibit the hemagglutination by Strepto-
coccus suis at nanomolar concentration (Fig. 13) [74].  
 Inhibition experiments of agglutination of human eryth-
rocyte by two types of S. Suis bacteria (PN and PO) were per-
formed. Complete inhibition using this tetravalent galabiose 
was found for 3 and 2 nM for each type of S. Suis bacteria 
respectively. This example was considered at that time as the 
first example of inhibition of bacteria adhesion at nanomolar 
range. 
 Pieters et al., described the preparation of galabiose den-
drimers and their inhibition activities against Streptococcus 
suis [75]. Assays to study the inhibition of hemagglutination 
of human erythrocytes induced by two subtypes of Strepto-
coccus suis (PN and PO) was performed. The MIC (minimal 
inhibitory concentration) required for complete inhibition of 
the agglutination process were measured. The MIC found for 
Fig. (11). Chemical structure of PAMAM dendronized oligourethane. 
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all compounds containing 2 (13), 4 (5), and 8 (3) galabioses 
with different linkers were in the nanomolar range (Fig. 14).  
 The octavalent galabiose PAMAM presented a MIC of 
0.3 nM for the PN subtype (3000 fold more potent than the 
monovalent compound) and the authors claim that this is the 
first example where a carbohydrate compound presents a 
subnanomolar activity in the inhibition of bacterial adhesion. 
Biosensor was used as a complementary experiment to test 
the activity of these compounds. Pigeon ovomucoid, a pro-
tein rich in galabiose was immobilized on the sensor chip 
surface of the biosensor. S. suis PN was flowed over this sur-
face in the presence or absence of inhibitors at different con-
centrations. IC50 were obtained for each compound in the 
range of 150-300 nM for divalent inhibitors and 7 nM for 
tetravalent compound and octavalent PAMAM. These stud-
ies provide important information about the role of the mo-
bility and orientation of ligands and valency of multivalent 
scaffolds in relationship with the enhancement of binding 
affinities. Fig. (13). Tetravalent galabiose. 
Fig. (12). Poly(propylene imine) 2G dendrimer (12).
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Staphylococcus aureus 
 Staphylococcal disease and its role in sepsis and abscess 
formation were described for the first time in 1880 and 1882 
by Ogston. More than 100 years later, Staphylococcus aureus
(a Gram-positive bacteria) remains a dangerous pathogen in 
humans that can cause illnesses ranging from minor skin 
infections to life-threatening diseases such as pneumonia, 
meningitis, endocarditis, Toxic shock syndrome (TSS), and 
septicemia [76].  
 The dendrimers described by Cooper et al. [77] and Ur-
banczyk-Lipkowska et al. [68,69] for E. coli were also tested 
against a Gram-positive bacteria Staphylococcus aureus
NCTC 4163. Very similar activities in this infection model 
with S. aureus were also found in the E. coli studies. 
Actinomyces naeslundii 
 A. naeslundii is a Gram-positive bacterium that colonizes 
oral cavities. During this colonization process, A. naeslundii
co-aggregate with Streptococcus oralis through galactose 
residues present at the surface of S. oralis and an adhesin of 
A. naeslundii pili [78]. Davis et al., have developed a new 
type of multivalent systems named glycodendriproteins con-
sisting in the functionalization of proteins with glycoden-
drons (Fig. 15) [79].  
 These types of structures mimicking glycoproteins 
avoided the problem of glycoforms. Galactose-dendri-pro-
teins were tested as potential inhibitors of co-aggregation of 
A. naeslundii and S. oralis. The dendriprotein with a flexible 
bi-antennary galactosyl structure was a potent inhibitor with 
an IC50 of 20 nM (a million fold more potent than lactose). 
This result opens a new avenue to design de novo glycopro-
teins with important biological activities.  
FUNGAL INFECTION 
 One of the most common infections produced by fungi is 
that caused by Candida albicans. C. albicans is a normal 
Fig. (14). Chemical structure of galabiose functionalized divalent system (13). 
Fig. (15). Tetravalent galactosyl dendriprotein. 
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inhabitant of the human mouth and gastrointestinal tract. 
Under normal circumstances, C. albicans colonizes humans 
with no harmful effects, although overgrowth may result in 
candidiasis in skin or mucosa [80]. Systemic candidiasis is 
often observed in immunocompromised individuals such in 
transplantation, malignancy or AIDS. Different forms of C. 
albicans are also recognized by different lectins that are ex-
pressed at the surface of target cells [81].  
 To our best knowledge, there is only one example de-
scribed by Urbanczyk-Lipkowska et al., where dendrimers 
are used as anti-infective agents in a C. albicans infection 
process. These authors have developed a low molecular mass 
lysine dendrimer with antimicrobial activity [68]. These 
small dendrimers are functionalized at the surface by arginin 
residues and presented minimal inhibition concentrations 
between 72 and 69 ?M.  
PRION PROTEIN INFECTION 
 Stanley Prusiner discovered almost 25 years ago a new 
infective agent, a protein named prion. The prion protein is 
the product of a normal gene expressed mainly in neural tis-
sue and presents several ?-helix and few ?-sheets in its natu-
ral configuration known as PrPC. This protein adopts an ab-
normal configuration upon contact with the ?-sheet-rich in-
fectious form of the protein known as PrPSc after scrapie, an 
old recognized disease of sheep [82]. These types of struc-
tures are found in several neurodegenerative disorders such 
as Creutzfeldt-Jakob disease in humans, bovine spongiform 
encephalopathy, etc. Prusiner et al., have demonstrated that 
highly branched polyamidoamine PAMAM dendrimers were 
able to eliminate PrPSc in a very efficient way. PAMAM 
generation 4.0 presenting 64 amine groups at the surface (see 
Fig. (10) for PAMAM 2G (11) with 16 amine groups or Fig. 
(16) for 3G (14) with 32 amine groups) was able to removed 
prion protein in a dose and time dependent manner with IC50
around 80 ng/mL [83,84].  
 For these experiments, chronically scrapie-infected neu-
roblastoma N2a (ScN2a) cells were used. In these studies 
was demonstrated that the size of the dendrimer and the 
number of amine groups at the surface were critical for an 
Fig. (16). PAMAM 3G (14).
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efficient activity. These compounds required an acidic media 
to destroy PrPSc; however, the mechanism to eliminate prion 
proteins was not clarified. It seems that the presence of den-
drimers make fibrils sensitive to protease K degradation. A 
potential use of these dendrimers as reagents for prion de-
contaminants to remove prions from skin, surgical instru-
ments, surfaces, etc. has been envisaged [84].  
 Very recently, Cladera et al., have studied the aggrega-
tion of the Alzheimer amyloid peptide A?1-28 and human 
prion protein PrP185-208 in the presence of PAMAM 
dendrimers [85-87]. Higher generations of PAMAM G3-G5 
led to a smaller amount of fibrils formed. 1?M of PAMAM 
G5 was enough to inhibit the fibril formation. The 
mechanism proposed was based on two actions: a) 
interaction of dendrimers with the peptide monomers 
inhibiting the fibril growth and b) breaking the existing 
fibrils.   Heegaard et al., have used a guanidinium modified den-
drimer (15) based on the second generation of poly (propyl-
ene imine) (PPI) (2) to destabilized the fibril formation of a 
peptide fragment of the PrP (106-126) in water at a concen-
tration of 20 ?M/mL (Fig. 17) [88].  
Fig. (17). Guanidinium modified poly(propylene imine) (PPI) 2G 
(15).
 The guanidinium groups at the surface were easily proto-
nated in water due to the high pKa compared with the amino 
groups of PPI. The effect produced by this dendrimer seems 
to solubilize the protein. 
 A final example described by Lehmann et al. using cati-
onic phosphorus-containing dendrimers (P-dendrimers) will 
be reviewed [89]. Protonated tertiary amine end-groups were 
presented at the surface of these compounds (Fig. 18).  
 The compounds presented some advantages in compari-
son with PAMAM dendrimers such as a higher stability 
against nucleophilic degradation due to the phosphorous 
atoms and the high hydrophilic nature, decreasing rapid 
elimination when applied. These dendrimers were able to 
clear PrPSc in the SN2a cells with IC50 in the nM range (600 
nM, 45 nM, and 75 nM for pd-G3, pd-G4, and pd-G5 respec-
tively). Again, the mechanism proposed was based on the 
interaction of the dendritic structures with the fibrils, disrupt-
ing these aggregates and doing easier their degradation by 
protease K. Cytotoxic studies demonstrated that these P-
dendrimers were less toxic than PAMAM and also they pre-
sented a wide biodistribution throughout the body. In vivo
studies using mice infected with PrPSc demonstrated that P-
dendrimers inhibited the generation of PrPSc in spleen. These 
authors considered that the treatment with P-dendrimers as a 
post-exposure prion prophylaxis could open an interesting 
therapeutic approach to prion diseases. 
VIRAL INFECTION 
 This is the area of application where more efforts have 
been done respect to develop new anti-infective agents based 
on dendrimers. Recently, a review describing dendrimers as 
antivirals has been published [90]. Here, we intend to update 
the information presented in that review with the most recent 
publications concerning dendrimers as antiviral drugs. 
Again, this section will be divided for each different viral 
agent.  
HIV-1, HIV-2, AND SIV 
 Infection by Human Immunodeficiency Virus (HIV) is a 
global health problem although, especially dramatic in de-
veloping countries in sub-Saharan Africa and Asia where the 
vast majority of infected patients do not have access to 
antiretroviral drugs. Most recent research in this topic is con-
centrated on vaccine development and mainly on developing 
microbicides [91,92]. Most of the work concerning dendrim-
ers is oriented to developing these microbicides of topical 
use. 
 We would like to focus mainly in one negatively-charged 
dendrimer which has been formulated as a Gel called 
SPL7013 (Fig. 19).  
 This dendrimer was developed by a pharmaceutical com-
pany in Australia Starpharma Pty Limited together with a 
large series of other dendritic compounds. Biological studies 
in vitro and in vivo with SPL7013 indicated that this com-
pound could be the best candidate to attain the market as the 
first dendrimer with a biomedical application. A study per-
formed by Dezutti et al., demonstrated that a formulation of 
SPL7013 (5%) showed a low epithelial toxicity and was 
highly effective to prevent infection by HIV-1 of PMBCs, 
macrophage and transfer of virus from epithelial cells to 
PMBCs [93]. These promising results indicated that this type 
of formulated drugs could be used as promising candidates to 
be applied as microbicides. More detailed studies about the 
toxicity of SPL7013 gel formulations were performed by 
Patton et al., [94]. A repeated daily vaginal use of 1-3% of 
SPL7013 gels were well tolerated (similar results were found 
to rectal use); however, 5% of SPL7013 produce deleterious 
effects on the cervicovaginal environments [94]. SPL7013 
was also tested in a HIV infection colorectal tissue explants 
model [95]. This study demonstrated the low toxicity of for-
mulated SPL7013 and the highly effectiveness in prevention 
HIV infection in this model. In vivo studies were carried out 
using SPL7013 gel as a topical microbicide in a vaginal 
transmission of SHIV in macaques [96]. The results showed 
that neither SPL7013 nor placebo gels produced any signs of 
mucosal irritation after vaginal application. SPL7013 (5%) 
gel protected 6 of 6 macaques (100% of protection) while 
SPL7013 (3%) gel protected only 83.3%. McCarthy et al.,
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Fig. (18). Chemical structures of phosphorous dendrimers pd-G3, pd-G4, and pd-G5. 
Fig. (19). Chemical structure of SPL7013.
from the company Starpharma Pty Limited described in de-
tail the process developed to achieve the lead compound 
SPL7013 [97]. Many parameters were evaluated to arrive to 
the final dendrimer structure easy to be prepared in large 
scale as a single molecule. The clinical drug is known as 
VivaGel and is the first dendrimer submitted to the United 
States Food and Drug Administration (FDA) as investiga-
tional new drug application in 2003. Also, Phase I clinical 
trials were carried out involving 36 healthy women with suc-
cessful results.  
 Another approach to inhibit HIV entry and dissemination 
is based on blocking the interaction with galactosyl ceramide 
as a receptor in CD4+ cells [98]. Blanzat, Turrin et al. have 
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prepared acid-terminated dendrimers non-covalently assem-
bled with galactosyl ceramide analogues [99]. Cinamic acid 
terminated dendrimers were combined with aminolactitol to 
form analogues of galactosyl ceramides (Fig. 20).  
 HIV inhibition activities and cytotoxicities of these den-
drimers were evaluated in vitro using CEM-SS cells (human 
T4-lymphoblastoid cell line) as model. The values found for 
each compound are represented in Table 5.
 It is clearly observed that the different IC50 found not 
only depend of the number of sugars at the surface but also 
of the size and shape of the dendritic core.  
 Other examples of dendrimers with anti-HIV activity are 
collected in the review of Schengrund et al. [90] 
Herpes Simplex Virus (HSV) Infection 
 Genital human herpes virus infection is one of the most 
prevalent sexual transmitted diseases (STDs). HSV-1 and 2 
cause mucocutaneous infection, such as herpes labialis and 
herpes genitalis. After primary or initial infection the virus 
persists for life in a latent form in neurons of the host, peri-
odically reactivating. Currently, no cure is available [100].  
Fig. (20). Non-covalent assembled galactosyl ceramides analogues dendrimers 1c-G1, 1c-G2, 2c-G0, and 2c-G1.
Table 5. Inhibition Activities for Galactosyl Ceramide Analogue Dendrimers 
Compound Number of sugars IC50 (?M) CC50 (?M)
monomer 1 50 70 
1c-G1 6 2.1 3.5 
1c-G2 12 1.1 2.9 
2c-G0 6 0.37 9.3 
2c-G1 12 0.12 3.9 
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 One of the promising compounds developed against HSV 
is a sulphated polylysine dendrimer named SPL2999 (also 
known as BRI-2999) which has been already reviewed (Fig. 
(21) [90].  
Fig. (21). Chemical structure of SPL2999 or BRI-2999. 
 An evolution of this compound is the dendrimer 
SPL7013 (commented previously as an anti-HIV agent). 
This dendrimer have been tested (formulated and unformu-
lated) as a microbicide candidate against genital herpes in 
mouse and guinea pig models and it was already analyzed in 
a previous review [90]. A new study concerning the antiviral 
efficacy, mechanism of action, and toxicity of SPL7013 has 
been recently published [101]. Vero cells were infected with 
2.0 ?g/mL of HSV-1 or 0.5 ?g/mL of HSV-2. Two types of 
experiments were performed, pre-treatment (PT) of cells 
with SPL7013 or treatment of infected cells (INF). The re-
sults are shown in Table 6.
 SPL7013 inhibited virus internalization of both HSV-1 
and HSV-2 at concentrations bigger than 3 ?g/mL. Also, 
SPL7013 showed post-exposure activity on HSV infection 
indicating a therapeutic activity. This type of dendrimers 
could be used in prevention and treatment of HSV infection 
with a pH independent activity. Again, SPL7013 has been 
demonstrated as a promising microbicide candidate in STIs. 
Influenza Virus Infection 
 Influenza virus is a RNA virus that infects mainly verte-
brates. There are 3 types of influenza: A, B, and C. Influenza 
A is the cause of all flu pandemics. This virus adheres to the 
target cells through the interaction of the main envelope gly-
coprotein: hemagglutinin (HA). HA recognizes sialic acid 
receptors on the host cell. It is known that monovalent sialic 
acid was able to prevent influenza A agglutination of chicken 
erythrocytes [102].  
 Whitesides et al., described in 1999 a pioneer work in the 
preparation of multivalent systems based on polyacrylamide 
functionalized with ?-sialoside groups (Fig. 22) [103].  
Fig. (22). ?-sialosyl functionalized polyacrylamide. 
 This glycopolymer strongly inhibited the agglutination of 
erythrocytes by influenza virus. Although this system is not a 
dendrimer (it is a glycopolymer), the work presented in this 
paper constitutes a milestone in the development of multiva-
lent systems for influenza and has inspired later work of 
other authors. In fact, most of the work concerning den-
drimeric structures development as anti-influenza virus in-
fection was based on a multimeric presentation of sialic acid 
at the surface of these structures. Baker et al. developed sys-
tems based on PAMAM as dendritic core functionalized with 
sialic acid as described in the original papers and in a recent 
review [90].  
Food-and-Mouth Disease Virus (FMDV) Infection  
 Food-and-mouth disease virus infects animals through 
the respiratory tract or skin abrasions and it is economically 
the most important disease in farm animals [104]. A very 
interesting approach to generate a vaccine against this infec-
tion has been described by Andreu et al. [105] A multivalent 
presentation of a lipidated cyclic peptide representing the 
main antigenic site of FMDV was preparing using a 
polylysine dendritic core (Fig. 23).  
 Guinea pig immunized with 500 ?g of a trivalent conju-
gate elicited antibodies with strong neutralizing activity.  
Ebola Virus Infection 
 Ebola Virus along with Marburg virus constitute the 
Filoviridae family that is responsible of sporadic outbreaks 
of hemorrhagic fever in Africa characterized by a high death 
rate [106]. There is not currently any vaccine or specific 
treatment available for these dangerous agents and only sup-
Table 6. Inhibition Activities of SPL7013 in a HSV-1 and HSV-2 Infection Model 
Virus HSV-1 HSV-2 
Treatment PT INF PT INF 
Mean EC50 (?g/mL) 2.0 6.1 0.5 3.8 
BHA.Lys.Lys2.Lys4.Lys8.Lys16(NHCSNH(Napth(SO3Na))32
BHA = NH
SP2999 or BRI-2999
OHO O
O
NH NH2
AcNH
HO
COO-
O O
OH
OH
mn
Dendrimers and Dendritic Polymers as Anti-infective Agents Anti-Infective Agents in Medicinal Chemistry, 2007, Vol. 6, No. 3    171 
Fig. (23). Lipidated cyclic peptide functionalized polylysine den-
drimer. 
portive measures can be provided for infected individuals. 
The envelope of Ebola virus consists of a trimer of a highly 
glycosilated glycoprotein that is recognized both by DC-
SIGN and DC-SIGNR/L-SIGN and it has been shown in
vitro that the presence of these molecules can significantly 
increase the infectivity facilitating entry in cis and in trans,
i.e. to susceptible neighbouring cells [23,24]. We have 
shown proof of principle that Ebola virus cellular infection 
enhancement by DC-SIGN can be blocked by a glycoden-
drimeric structure with CRDs specificity [107,108]. Our 
strategy was oriented to inhibit the entry of Ebola virus 
blocking the DC-SIGN lectin, a receptor that was described 
as one of the potential gate of entrance for this virus [23].  
 We have been involved during the last four years in de-
veloping glycodendritic structures based on the commer-
cially available dendritic polymer Boltorn as multivalent 
core (Fig. 24) [107,108].  
 These dendritic structures could inhibit the infection 
process in a DC-SIGN dependent manner. Our preliminary 
results showed that at least the third generation of this den-
dritic polymer (BH30) functionalized with 32 mannoses at 
the surface presented a promising antiviral activity in a pseu-
dotyped viral particles model of Ebola virus infection in cis
and in trans with IC50 in the sub-micromolar range [108]. 
This is the first demonstration of potential application of a 
Fig. (24). Mannosyl functionalized dendritic polymer Boltorn 3G (BH30).  
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dendrimer structure as a filovirus antiviral. These types of 
glycostructures were able to block the DC-SIGN receptor at 
the cell surface inhibiting the entrance of the pathogen and 
therefore, they could be used as microbicides.  
PERSPECTIVES 
 Since the discovery and preparation of the first dendritic 
compound almost 3 decades ago, many attempts have been 
done by several groups to apply these dendritic structures in 
biomedicine. Most of the structures used as anti-infective 
agents are based on poly(amido amine) (PAMAM) and 
poly(propylene imine) (PPI) dendrimers. These are two well 
known structures and both of them commercially available 
up to generation 5 at least. Chemical manipulation of the 
dendritic surface (most of the time by the introduction of 
carbohydrates) are produced a large number of new struc-
tures with interesting antimicrobial properties as has been 
described along this review. This long road is close to be 
successful with the first dendritic compound in clinical Phase 
I showing promising antiviral properties. There is still a lot 
of work to do concerning the behaviour of these structures, 
their pharmacokinetics, etc. The chemistry of the dendrimer 
surface allows the introduction of diverse functional groups 
that control not only the physical-chemical properties of the 
dendrimers but also can modulate the activity of these com-
pounds. Much work has been done respect to decrease the 
cytotoxicity that this type of entities can present. Changes of 
the functional groups at the surface or even the chemical 
structure of the core can be manipulated to achieve low tox-
icities, the first step required to reach a potential clinical ap-
plication. We consider that dendrimers and dendritic poly-
mers have to play a key role in the nanoscience field in next 
years. They are very flexible structures to be easily manipu-
lated and modulated by chemists to achieve new properties 
and pursue future applications in biomedical science. In fact, 
the knowledge provided by all the research summarized 
above, establishes the bases for new accomplishments in the 
area of anti-infective agents with a broad spectrum of appli-
cations. Having a compound in clinical Phase I means a real 
step towards achieving the first milestone. We hope that in 
the next few decades, we could have derivatized dendritic 
compounds to be used as pharmaceuticals.  
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ABBREVIATIONS 
cAMP = Cyclic Adenosine Monophosphate 
Cer = Ceramide 
CLR = C-type Lectin Receptor 
CMV = Cytomegalovirus 
CRD = Carbohydrate Recognition Domain 
CTB = Cholera Toxin B subunit 
DC = Dendritic Cell 
DC-SIGN = Dendritic Cell-Specific ICAM-3 Grabbing 
Non-Integrin 
DC-SIGNR = Dendritic Cell-Specific ICAM-3 Grabbing 
Non-Integrin Related 
ELISA = Enzyme-Linked Immunosorbent Assay 
FDA = Food and Drug Administration 
FMDV = Food-and-Mouth Disease Virus 
Gal = Galactose 
GalNAc = N-Acetyl Galactosamine 
Glc = Glucose 
GlcNAc = N-Acetyl Glucosamine 
HA = Hemagglutinin 
HCV = Hepatitis C Virus 
HIV = Human Immunodeficiency Virus 
HSV = Herpes Simplex Virus 
ICAM-3 = Intercellular Adhesion Molecule 3 
Le = Lewis 
LPS = Lipopolysaccharide 
L-SIGN = Liver/lymph node-Specific ICAM-3 Grab-
bing Non-Integrin 
LT = Heat Label Enterotoxin 
Man = Mannose 
ManLAM = Mannosylated Lipoarabinomannan 
MHC = Major Histocompatibility Complex 
MIC = Minimal Inhibitory Concentration 
NeuNAc = N-Acetyl Neuraminic Acid 
NLR = NOD-like Receptors 
PAMAM = Poly(amido amine) 
PAMP = Pathogen-associated Molecular Pattern 
PMBC = Peripheral Mononuclear Blood Cell 
PPI = Poly(propylene imine) 
PrPC = Prion Protein normal form 
PrPS or PrPSc = Prion Protein Scrapie form 
PRR = Pattern-Recognition Receptor 
SARS = Severe Acute Respiratory Syndrome 
SHIV = Simian Human Immunodeficiency Virus 
SLT = Shiga-Like Toxin 
STD = Sexual Transmitted Disease 
STI = Sexual Transmitted Infection 
Stx = Shiga Toxin 
TLR = Toll-Like Receptor 
Trp = Tryptophan 
TSI = Toxic Shock Syndrome 
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